Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s43018-023-00603-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SIGLEC9 tips the myeloid balance in glioblastoma.
Nat Cancer
September 2023
Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Siglecs as targets for therapy in immune-cell-mediated disease.
Trends Pharmacol Sci
May 2009
Department of Chemical Physiology, The Scripps Research Institute, La Jolla CA 92037, USA.
The sialic-acid-binding immunoglobulin-like lectins (siglecs) comprise a family of receptors that are differentially expressed on leukocytes and other immune cells. The restricted expression of several siglecs to one or a few cell types makes them attractive targets for cell-directed therapies. The anti-CD33 (also known as Siglec-3) antibody gemtuzumab (Mylotarg) is approved for the treatment of acute myeloid leukemia, and antibodies targeting CD22 (Siglec-2) are currently in clinical trials for treatment of B cell non-Hodgkins lymphomas and autoimmune diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!